BICYCLE THERAPEUTICS ($BCYC) posted quarterly earnings results on Thursday, May 1st. The company reported earnings of -$0.88 per share, missing estimates of -$0.86 by $0.02. The company also reported revenue of $9,980,000, beating estimates of $7,939,221 by $2,040,779.
You can see Quiver Quantitative's $BCYC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BICYCLE THERAPEUTICS Insider Trading Activity
BICYCLE THERAPEUTICS insiders have traded $BCYC stock on the open market 42 times in the past 6 months. Of those trades, 10 have been purchases and 32 have been sales.
Here’s a breakdown of recent trading of $BCYC stock by insiders over the last 6 months:
- BROS. ADVISORS LP BAKER has made 10 purchases buying 1,485,397 shares for an estimated $21,230,384 and 0 sales.
- TRAVIS ALVIN THOMPSON (CHIEF ACCOUNTING OFFICER) has made 0 purchases and 11 sales selling 11,170 shares for an estimated $226,905.
- KEVIN LEE (CHIEF EXECUTIVE OFFICER) has made 0 purchases and 4 sales selling 17,799 shares for an estimated $216,564.
- ALISTAIR MILNES (CHIEF OPERATING OFFICER) has made 0 purchases and 4 sales selling 7,685 shares for an estimated $95,160.
- MICHAEL SKYNNER (CHIEF TECHNOLOGY OFFICER) has made 0 purchases and 4 sales selling 6,075 shares for an estimated $74,412.
- SANTIAGO ARROYO (CHIEF DEVELOPMENT OFFICER) sold 4,943 shares for an estimated $69,646
- NIGEL CROCKETT (CHIEF BUSINESS OFFICER) has made 0 purchases and 2 sales selling 3,519 shares for an estimated $50,200.
- MICHAEL CHARLES FERGUSON HANNAY (CHIEF PROD & SUPPLY CHAIN OFF) has made 0 purchases and 4 sales selling 2,851 shares for an estimated $35,735.
- ALETHIA YOUNG (Chief Financial Officer) has made 0 purchases and 2 sales selling 1,610 shares for an estimated $21,379.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BICYCLE THERAPEUTICS Hedge Fund Activity
We have seen 42 institutional investors add shares of BICYCLE THERAPEUTICS stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- POINT72 ASSET MANAGEMENT, L.P. added 3,655,101 shares (+406.2%) to their portfolio in Q4 2024, for an estimated $51,171,414
- DEEP TRACK CAPITAL, LP removed 2,271,920 shares (-64.0%) from their portfolio in Q4 2024, for an estimated $31,806,880
- SIREN, L.L.C. added 1,839,398 shares (+inf%) to their portfolio in Q4 2024, for an estimated $25,751,572
- BAKER BROS. ADVISORS LP added 1,485,397 shares (+15.8%) to their portfolio in Q4 2024, for an estimated $20,795,558
- RA CAPITAL MANAGEMENT, L.P. removed 1,159,523 shares (-51.5%) from their portfolio in Q4 2024, for an estimated $16,233,322
- FCPM III SERVICES B.V. added 1,112,369 shares (+47.5%) to their portfolio in Q4 2024, for an estimated $15,573,166
- POLAR CAPITAL HOLDINGS PLC removed 1,002,780 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $14,038,920
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BICYCLE THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $BCYC in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Outperform" rating on 12/18/2024
To track analyst ratings and price targets for BICYCLE THERAPEUTICS, check out Quiver Quantitative's $BCYC forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
